JP5837095B2 - Ａｌｋ阻害剤の使用方法 - Google Patents

Ａｌｋ阻害剤の使用方法 Download PDF

Info

Publication number
JP5837095B2
JP5837095B2 JP2013552637A JP2013552637A JP5837095B2 JP 5837095 B2 JP5837095 B2 JP 5837095B2 JP 2013552637 A JP2013552637 A JP 2013552637A JP 2013552637 A JP2013552637 A JP 2013552637A JP 5837095 B2 JP5837095 B2 JP 5837095B2
Authority
JP
Japan
Prior art keywords
alk
compound
isopropoxy
chloro
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013552637A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014504646A5 (enExample
JP2014504646A (ja
Inventor
ナンシン・リ
ジェニファー・エル・ハリス
ピーター・マクナマラ
ファンシャン・サン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IRM LLC
Original Assignee
IRM LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45582065&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5837095(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by IRM LLC filed Critical IRM LLC
Publication of JP2014504646A publication Critical patent/JP2014504646A/ja
Publication of JP2014504646A5 publication Critical patent/JP2014504646A5/ja
Application granted granted Critical
Publication of JP5837095B2 publication Critical patent/JP5837095B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2013552637A 2011-02-02 2012-02-02 Ａｌｋ阻害剤の使用方法 Active JP5837095B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161438878P 2011-02-02 2011-02-02
US61/438,878 2011-02-02
PCT/US2012/023669 WO2012106540A1 (en) 2011-02-02 2012-02-02 Methods of using alk inhibitors

Publications (3)

Publication Number Publication Date
JP2014504646A JP2014504646A (ja) 2014-02-24
JP2014504646A5 JP2014504646A5 (enExample) 2014-07-24
JP5837095B2 true JP5837095B2 (ja) 2015-12-24

Family

ID=45582065

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013552637A Active JP5837095B2 (ja) 2011-02-02 2012-02-02 Ａｌｋ阻害剤の使用方法

Country Status (22)

Country Link
US (1) US8703787B2 (enExample)
EP (1) EP2670401B1 (enExample)
JP (1) JP5837095B2 (enExample)
KR (1) KR101521861B1 (enExample)
CN (1) CN103458881B (enExample)
AU (1) AU2012212142B2 (enExample)
BR (1) BR112013019643B1 (enExample)
CA (1) CA2824092C (enExample)
CY (1) CY1116662T1 (enExample)
DK (1) DK2670401T3 (enExample)
EA (1) EA023404B1 (enExample)
ES (1) ES2543567T3 (enExample)
HR (1) HRP20150946T1 (enExample)
HU (1) HUE025395T2 (enExample)
ME (1) ME02200B (enExample)
MX (1) MX2013008791A (enExample)
PL (1) PL2670401T3 (enExample)
PT (1) PT2670401E (enExample)
RS (1) RS54189B1 (enExample)
SI (1) SI2670401T1 (enExample)
SM (1) SMT201500300B (enExample)
WO (1) WO2012106540A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102156398B1 (ko) 2012-11-06 2020-09-15 상하이 포천 파마슈티컬 씨오 엘티디 Ａｌｋ 키나아제 억제제
IN2015DN04175A (enExample) * 2012-11-07 2015-10-16 Novartis Ag
CN104109149B (zh) * 2013-04-22 2018-09-28 苏州泽璟生物制药有限公司 氘代的二氨基嘧啶化合物以及包含该化合物的药物组合物
ITMI20131124A1 (it) * 2013-07-04 2015-01-05 Univ Milano Bicocca 2-acilamminotiazoli per il trattamento del cancro
WO2015003658A1 (en) * 2013-07-11 2015-01-15 Betta Pharmaceuticals Co., Ltd Protein tyrosine kinase modulators and methods of use
JP6479812B2 (ja) * 2013-08-28 2019-03-06 ノバルティス アーゲー 細胞増殖性疾患を治療するためのａｌｋ阻害剤とｃｄｋ阻害剤との組合せ
CN104672214B (zh) * 2013-12-03 2019-04-12 上海翰森生物医药科技有限公司 具有alk抑制活性的化合物及其制备与用途
MX2016008362A (es) * 2013-12-23 2016-09-08 Novartis Ag Combinaciones farmaceuticas.
CN104876914B (zh) * 2014-02-28 2017-04-19 山东轩竹医药科技有限公司 嘧啶衍生物类间变性淋巴瘤激酶抑制剂
KR101656382B1 (ko) * 2014-02-28 2016-09-09 한국화학연구원 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물
KR101733733B1 (ko) * 2014-06-17 2017-05-11 한국화학연구원 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물
CN105524045B (zh) * 2014-10-22 2020-04-10 山东轩竹医药科技有限公司 四环类间变性淋巴瘤激酶抑制剂
CN106146525B (zh) * 2015-04-10 2018-11-02 山东轩竹医药科技有限公司 三并环类间变性淋巴瘤激酶抑制剂
US10259816B2 (en) 2015-04-24 2019-04-16 Guangzhou Maxinovel Pharmaceuticals Co., Ltd. Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof
CN106699743B (zh) 2015-11-05 2020-06-12 湖北生物医药产业技术研究院有限公司 嘧啶类衍生物及其用途
CN106220608B (zh) * 2016-07-25 2018-11-27 安润医药科技（苏州）有限公司 二苯氨基嘧啶及三嗪化合物、其药用组合物及用途
CN107698603B (zh) * 2016-08-09 2022-04-08 南京红云生物科技有限公司 噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用
CN109715620B (zh) * 2016-08-29 2022-05-06 密歇根大学董事会 作为alk抑制剂的氨基嘧啶
CN111484484B (zh) * 2020-04-13 2021-11-23 沈阳药科大学 含芳杂环的2,4-二芳氨基嘧啶衍生物及其制备与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
JP4607879B2 (ja) * 2003-08-15 2011-01-05 ノバルティス アーゲー 新生物疾患、炎症および免疫障害の処置に有用な２，４−ピリミジンジアミン
GB0419161D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
ES2444222T3 (es) 2006-07-10 2014-02-24 Goji Limited Preparación de alimentos
CA2598893C (en) * 2006-10-11 2012-04-10 Astellas Pharma Inc. Eml4-alk fusion gene
RS53588B1 (sr) * 2006-12-08 2015-02-27 Irm Llc Jedinjenja i kompozicije kao inhibitori protein kinaza
BRPI0720264B1 (pt) * 2006-12-08 2022-03-03 Novartis Ag Compostos e composições como inibidores de proteína cinase
CA2720946C (en) * 2008-04-07 2013-05-28 Irm Llc Compounds and compositions as protein kinase inhibitors

Also Published As

Publication number Publication date
HUE025395T2 (en) 2016-02-29
PT2670401E (pt) 2015-10-12
EA201391114A1 (ru) 2013-12-30
CN103458881B (zh) 2015-08-12
SMT201500300B (it) 2016-01-08
CA2824092C (en) 2020-06-30
MX2013008791A (es) 2013-10-07
DK2670401T3 (en) 2015-09-07
KR20130121174A (ko) 2013-11-05
WO2012106540A1 (en) 2012-08-09
EP2670401B1 (en) 2015-06-10
SI2670401T1 (sl) 2015-10-30
PL2670401T3 (pl) 2015-11-30
EP2670401A1 (en) 2013-12-11
BR112013019643B1 (pt) 2022-04-19
ES2543567T3 (es) 2015-08-20
US20130296357A1 (en) 2013-11-07
EA023404B1 (ru) 2016-05-31
CY1116662T1 (el) 2017-03-15
AU2012212142A1 (en) 2013-08-15
KR101521861B1 (ko) 2015-05-21
US8703787B2 (en) 2014-04-22
CN103458881A (zh) 2013-12-18
HRP20150946T1 (hr) 2015-10-09
BR112013019643A2 (pt) 2016-10-04
JP2014504646A (ja) 2014-02-24
CA2824092A1 (en) 2012-08-09
ME02200B (me) 2016-02-20
RS54189B1 (sr) 2015-12-31
AU2012212142B2 (en) 2015-09-24

Similar Documents

Publication Publication Date Title
JP5837095B2 (ja) Ａｌｋ阻害剤の使用方法
EP2872142A1 (en) Method of treating gastrointestinal stromal tumors
US12414945B2 (en) Therapeutic agent for breast cancer
US20160287585A1 (en) Treatment of Lung Cancer with Inhibitors of Glutaminase
JP7065103B2 (ja) エクソン１８及び／又はエクソン２１変異型ｅｇｆｒ選択的阻害剤
CN105873440A (zh) 适用于治疗癌症的用于抑制tie2激酶的方法
JPWO2018079310A1 (ja) エクソン２０挿入変異型ｅｇｆｒ選択的阻害剤
US20200375970A1 (en) Therapeutic agent for hepatocellular carcinoma
JP6059224B2 (ja) ピラジノ−トリアジン誘導体を含む非小細胞性肺癌の予防および治療用組成物
TW201625254A (zh) 以吡羧醯胺化合物作為有效成分之醫藥組成物
JP2024514098A (ja) ＥｒｂＢ２突然変異体を標的とする阻害薬の調製における化合物の使用
EP2177222B1 (en) Pyrimidylaminobenzamide derivatives for the treatment of neurofibromatosis
TW202140005A (zh) 用於治療發炎疾病之新穎藥物
KR20250105460A (ko) Kras 억제제 및 shp2 억제제를 포함하는 조합 요법
HK40079036A (en) Quinoline derivative for treating non-small cell lung cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140604

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140604

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150716

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20151006

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20151104

R150 Certificate of patent or registration of utility model

Ref document number: 5837095

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250